SIGA Technologies Inc. reports developments as a commercial-stage pharmaceutical company focused on infectious-disease countermeasures, with a primary focus on orthopoxviruses. Its recurring updates center on TPOXX (tecovirimat), including oral and IV product sales, deliveries to large institutional customers and international governments, Strategic National Stockpile activity, and procurement contracts.
Company news also covers quarterly and annual results, research and development revenue, BARDA 19C development funding for pediatric and manufacturing activities, regulatory developments for tecovirimat indications, business update calls, and capital actions such as special cash dividends on common stock.
SIGA Technologies (SIGA) will host a business update webcast and conference call on November 9, 2026, following its third-quarter financial results release. The call begins at 4:30 P.M. ET, with CEO Diem Nguyen and CFO Daniel Luckshire participating. A live and archived webcast will be available in the Investor Relations section of the company’s website.
SIGA Technologies (Nasdaq: SIGA) secured a Canadian defence contract for oral TPOXX valued at up to approximately $15 million.
Public Services and Procurement Canada awarded the contract on behalf of the Canadian Department of National Defence for purchases by March 31, 2031. Approximately $9 million represents firm commitments over the first three years; approximately $6 million depends on the department exercising options. This is the department's second TPOXX contract through the procurement agency. Final delivery under the prior contract occurred in 2025. Oral TPOXX, an antiviral for smallpox, received Health Canada approval in November 2021.
SIGA (Nasdaq: SIGA) reported second quarter 2026 product sales of $37.9 million and total revenues of $41.0 million, down from $79.1 million and $81.1 million in Q2 2025. Q2 2026 operating income was $13.9 million and net income was $12.5 million, or $0.17 per diluted share.
For the six months ended June 30, 2026, product sales were $41.4 million and total revenues $47.2 million, compared with $84.9 million and $88.2 million in 2025. The company delivered approximately $37 million of TPOXX in Q2 2026, including $24 million of IV TPOXX to the U.S. strategic national stockpile under the 19C contract and $13 million of oral TPOXX to two international customers, completing the last 19C procurement order. As of June 30, 2026, SIGA held $117.6 million in cash and cash equivalents and paid a $0.60 per share special cash dividend in April 2026.
SIGA (Nasdaq: SIGA) will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 6, 2026. CEO Diem Nguyen and CFO Daniel Luckshire will participate. The live webcast and archived replay will be available in the Investor Relations section of SIGA’s website, with phone access and two-week replay via provided domestic and international dial-in numbers and Conference ID 11157253.
SIGA (Nasdaq: SIGA) reported Q1 2026 results and provided a business update on May 7, 2026. Key metrics: product sales $3.5M, total revenues $6.2M, operating loss $5.3M, and net loss $3.5M for the three months ended March 31, 2026.
The company expects to deliver about $13M of oral TPOXX in Q2 2026 and roughly $26M of IV TPOXX to the U.S. SNS by end of Q3 2026; it also signed an exclusive MENA license with Hikma and paid a special $0.60 per-share cash dividend in April 2026.
SIGA (Nasdaq: SIGA) will host a webcast and conference call for a business update at 4:30 P.M. ET on Thursday, May 7, 2026. CEO Diem Nguyen and CFO Daniel Luckshire will participate. The live webcast and archived replay will be available in the Investor Relations section of the company website.
Dial-in numbers and a replay Conference ID (1158847) are provided for domestic and international callers; the replay will be available for two weeks.
SIGA (NASDAQ: SIGA) announced a special cash dividend of $0.60 per share, payable April 23, 2026, to shareholders of record at the close of business on April 7, 2026. The dividend equals the special dividend level declared in April 2025.
The company said this distribution reflects its balance sheet strength and focus on maximizing shareholder value while continuing programs to support government preparedness for potential smallpox outbreaks.
SIGA (Nasdaq: SIGA) reported 2025 results and a business update on March 10, 2026. The company generated $88.0M in product revenues in 2025 and reported $24M of pre-tax operating income, secured $27M of additional U.S. government funding, and received a $13M international procurement order for oral TPOXX in January 2026.
SIGA noted deliveries to the U.S. Strategic National Stockpile in 2025 and expects CHMP guidance on tecovirimat indications in March 2026. A conference call and webcast are scheduled for March 10, 2026 at 4:30 PM ET.
SIGA (Nasdaq: SIGA) will host a business update webcast and conference call on March 10, 2026 at 4:30 P.M. ET. Management participants include CEO Diem Nguyen and CFO Daniel Luckshire. The live webcast and an archived replay will be available via the company's Investor Relations website. Dial‑in numbers and a two‑week replay access with Conference ID 1122478 are provided for domestic and international callers.
SIGA (Nasdaq: SIGA) reported results for the three and nine months ended September 30, 2025, and will host a conference call on November 6, 2025 at 4:30 P.M. ET. For the first nine months of 2025 the company generated $85.8M in product sales and $90.8M total revenues, and reported $33M pre-tax operating income.
Year-to-date activity includes $53M oral TPOXX and $26M IV TPOXX deliveries to the U.S. Strategic National Stockpile, a $26M IV TPOXX procurement order from the U.S. Government, $27M of BARDA 19C funding added in 2025, regulatory approval of TEPOXX in Japan, and a $0.60 special cash dividend paid May 15, 2025.